Takeda Reports Results for the First Half of FY2015Confirms Management Guidance for the Full Year
Takeda Pharmaceutical Company Limited (TOKYO:4502):
First half results aligned with management guidance
- Underlying revenue +3.8% year-to-year (reported revenue growing +6.2% to 904 billion yen)
- Underlying Core Earnings +3.7% year-to-year (operating profit -5.4% to 110.4 billion yen)
Continued performance of Takeda's strategic growth drivers in the first half
- Gastroenterology underlying revenue +28.7%, oncology up +1.6% year-to-year
- Emerging markets underlying revenue +7.1% year-to-year, with particularly strong contributions from Russia and China
- Consolidated underlying revenue of gastroenterology, oncology and emerging markets – Takeda's growth drivers – is +10.0% year-to-year
First half growth supported by innovative new products
- Entyvio success continues to support more than $2 billion peak sales target
- Brintellix and Adcetris show steady growth
- Azilva and Lotriga continue to grow strongly in Japan
- Year-to-year underlying revenue growth in U.S. +12.0% (driven by Entyvio and Brintellix), Europe and Canada +1.5% (Entyvio and Adcetris), and emerging markets +7.1% (Russia and China)
- Strong growth of new products in Japan. Underlying revenue in Japan decreased by 3.4% year-to-year as a result of increasing generic penetration
Efficiency gains continue
- Project Summit achieved 11 billion yen of cost savings in the first half of FY2015
- On track to deliver more than 20 billion yen savings this fiscal year
Affirming management guidance for profitable growth in FY2015
- Low single-digit underlying revenue growth in FY2015, with underlying core earnings growth higher than underlying revenue growth, and underlying core EPS growth higher than underlying core earnings growth
Christophe Weber, President and Chief Executive Officer of Takeda, commented:
"In the first half of FY2015, Takeda continued its turnaround with underlying revenue growth of 3.8%, led by our growth drivers of gastroenterology, oncology and emerging markets. Operating profit was down in the first half of the year, mainly due to an increase in expenses for several recent launches and in R&D, as planned, but underlying core earnings increased by 3.7%, getting closer to underlying revenue growth. On the basis of our first-half results, we confirm our full-year management guidance."
Key figures for H1 of FY2015
|FY 2014||FY 2015||Growth|
|Core Earnings 1||169.9||177.5||+4.5%||+3.7%|
|Net Profit 3||61.4||54.4||-11.5%||–|
|EPS||78 yen||69 yen||-11.2%||–|
|Core EPS||134 yen||135 yen||+1.2%||+7.9%|
1 Core Earnings is calculated from operating profit by
excluding the impact of exceptional items, such as purchase accounting,
amortization and impairment loss of intangible assets, restructuring
costs and litigation costs.
2 Underlying performance aims at understanding the real performance of the business. Underlying Revenue and Underlying Core Earnings excludes the same as above and adjusted for acquisitions/divestments and foreign exchange.
3 Attributable to the owners of the company
Underlying revenue growth in the first half was +3.8%, Underlying Core Earnings was +3.7% and Underlying Core EPS was +7.9%, with no changes in our management guidance for FY2015. Reported revenue grew +6.2% to 904.0 billion yen. An increase in expenses for new launch products, as well as a decrease in other income related to sale of real estate in 2014, resulted in a year-to-year decline in Operating Profit, Net Profit and EPS, by 6.2 billion yen, 7.1 billion yen and 9 yen, respectively. These measures have improved in the second quarter compared to the first quarter.
Underlying revenue growth was mainly driven by Takeda's growth drivers, which are gastroenterology, oncology and emerging markets. Gastroenterology grew by +28.7% year-to-year, driven by Entyvio. Oncology revenue, including Velcade and Adcetris, increased by +1.6%. Emerging markets revenue grew by +7.1%, led by Value Brands (branded generics and OTC), with strong growth in Russia and China. Performance in the U.S. (+12.0% underlying revenue growth) and Europe and Canada (+1.5%) also contributed to revenue growth. In Japan, products such as Azilva and Lotriga contributed to revenue growth, but as a result of increasing generic competition, total revenue declined -3.4%.
Project Summit – a company-wide strategic initiative to increase efficiency – continued to produce results, with 11 billion yen savings in the first half. Execution of Summit initiatives in recent months include business restructuring programs, further optimization of production capacity utilization, and continued operational efficiency. A new global procurement organization also contributed by leveraging effective external spending. Efficiency initiatives as part of Project Summit remain on track, and Takeda is committed to continued operational efficiency.
Entyvio is expected to be a key global contributor to Takeda's sales growth over the next few years, and Azilva, Lotriga, and Takecab are the products that are expected to enable Takeda to maintain a leading position in Japan. As part of the ongoing efforts of the R&D organization, ixazomib for relapsed/refractory multiple myeloma was granted accelerated assessment status in Europe in July, and Priority Review status in the U.S. in September 2015. In Japan, Takeda submitted a New Drug Application for the fixed-dose combination tablet of Nesina and metformin, and received approval for Leuplin 24 week depot for the treatment of prostate cancer and premenopausal breast cancer and for Copaxone for the treatment of multiple sclerosis in September 2015.
Takeda confirmed its management guidance for FY2015, leading to long-term sales and profit growth.
Management Guidance for FY2015
|Underlying Revenue||Low single digit|
|Underlying Core Earnings||Higher than underlying revenue growth|
|Underlying Core EPS||Higher than underlying core earnings growth|
For more details on Takeda’s FY2015 H1 results and other financial information please visit http://www.takeda.com/investor-information/results/
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda (TOKYO:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
Takeda Pharmaceutical Company Limited
Noriko Higuchi, +81-(0)3-3278-2306
Tsuyoshi Tada, +81 (0)3-3278-2417
English media and media outside Japan
Tobias Cottmann, +41-79-217-7252
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
E Ink and LTS Partner to Develop Smart Patch to Improve Medical Management23.10.2017 07:00 | Pressemelding
E Ink Holdings, "E Ink" (8069.TW), the leading innovator of electronic ink technology and LTS Lohmann-Therapie Systeme AG, “LTS” leading in the development and manufacturing of transdermal therapeutic systems, today announced their partnership to develop a “Smart Patch” prototype. The Smart Patch prototype is a transdermal therapeutic system (TTS) that delivers medication to patients in a convenient, controlled and comfortable manner and features an E Ink display to deliver and convey relevant information about patch performance. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171023005449/en/ The “Smart Patch” prototype features an E Ink display to convey relevant information about patch performance to patients. (Photo: E Ink Holdings) According to a report conducted by the New England Healthcare Institute
MaxLinear and Corinex to Use G.hn for Open Smart Metering Solution23.10.2017 06:00 | Pressemelding
MaxLinear, Inc. (NYSE:MXL), a leading provider of radio frequency (RF), analog and mixed-signal integrated circuits for the connected home, wired and wireless infrastructure, and industrial and multimarket applications and Corinex, a unique supplier of broadband solutions (BPL) for smart metering and smart grid infrastructure improving grid operational efficiency, security and integration of renewable energy and EV’s today announced that they will cooperate to create a broadband utility infrastructure solution based on standard ITU-T G.hn technology to enable smart metering and other smart grid applications. The G.hn solution will address the growing interest of electricity utilities in leveraging broadband powerline networks for Smart Grid applications, while ensuring multi-vendor interoperability, openness and easy integration into a wide range of Smart Meters and Smart Grid infrastr
NTT Communications to Share Industry Views with Global Carrier Community at Capacity Europe 2017 in London23.10.2017 06:00 | Pressemelding
Executives from NTT Communications (NTT Com), the global data and IP services arm of Fortune Global 500 telecom leader NTT (TYO: 9432), will play a prominent speaking role at this year’s Capacity Europe conference in London – Europe’s largest annual meeting for the global carrier community. During the conference, which runs October 24-26 at the Intercontinental London 02, NTT Com executives will participate in three panels that provide expert analysis and perspective on trending industry topics including the Internet of Things (IoT), network security and the importance of innovation and leadership. NTT Com is in a unique position to address global wholesale trends and opportunities as the global carrier consistently ranks as one of the top IP network providers worldwide. “Coming together as an industry to share insights and perspective is not only beneficia
ADC Therapeutics Announces Closing of $200 Million Private Financing to Fund Two Lead Programs Through Registrational Trials23.10.2017 04:55 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it has raised $200 million through a private placement. The financing was oversubscribed and supported by both existing and new investors, including Auven Therapeutics, Redmile, the Wild Family Office and AstraZeneca. The proceeds will be used to progress ADCT-301 and ADCT-402 into planned registrational trials in 2018. Both candidates are currently in four clinical studies in important sub-types of lymphoma and leukemia. ADCT will also advance ADCT-301 into a combination study for solid tumors. Further it will allow the Company to continue the development of the Phase I study of ADCT-502 in patients with advanced solid tumors with HER2 expression, to file INDs for ADCT-602 and ADCT-6
Mitsui Chemicals Tohcello, Inc. Establishes a New Company in Taiwan23.10.2017 02:00 | Pressemelding
Mitsui Chemicals, Inc. (Head Office: Minato-ku, Tokyo; President & CEO: Tsutomu Tannowa) announced that its wholly owned subsidiary, Mitsui Chemicals Tohcello, Inc. (Head Office: Chiyoda-ku, Tokyo; President & CEO: Yoshihisa Fujimaki) has decided to establish a company in Taiwan that will manufacture and sell the ICROS™Tape, a tape for semiconductor manufacturing. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171022005001/en/ ICROS(TM)Tape (Photo: Business Wire) The ICROS™Tape is a protective tape used for semiconductor manufacturing. It holds the world’s largest market share as a protective tape for the back grinding process of silicon wafer. The semiconductor market is experiencing growing demand attributable in part to the growth of mobile terminals. Demand is expected to continue to grow a
Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201720.10.2017 21:00 | Pressemelding
Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom